Hepatitis C virus (HCV) infection can cause serious liver disease. Efforts to eliminate the virus involve the development of novel drugs designed to disrupt viral replication. One of the ways to inhibit the virus is by targeting the HCV enzyme NS3/4A protease. MK-5172 is a potent protease inhibitor recently approved by the FDA for the treatment of HCV. As part of this project, I synthesized four new analogues of MK-5172. These analogues, which lack the methoxy group on the quinoxaline, are either linear or have different macrocyclization than MK-5172. The compounds were tested for enzyme inhibitory activity using kinetic assays. The new macrocyclic analogues show potent inhibitory activity against wild-type NS3/4A protease and the D168A drug resistant variant.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Giroux, Michael James

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042816-091338

Advisor

• Dempski, Robert E.

Year

• 2016

Sponsor

• University of Massachusetts Medical School

Date created

• 2016-04-28

Resource type

• Major Qualifying Project

Major

• Biochemistry

Rights statement

• In Copyright